Punctal and canalicular stenosis associated with systemic fluorouracil therapy : report of five cases and review of the literature by Brink, H.M.A. & Beex, L.V.A.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/20959
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Documenta Ophthalmologica 90: 1-6, 1995.
©  1995 Kluwer Academic Publishers. Printed in the Netherlands.
Punctal and canalicular stenosis associated with 
systemic iluorouracil therapy
Report of five cases and review of the literature 
H.M.A. BRINK1 & L.V.A.M BEEX2
} ^
Institute o f Ophthalmology and Department of Endocrinology , Nijmegen University 
Hospital, Nijmegen, The Netherlands
Accepted 25 March 1995
Key words: Canalicular stenosis, Punctal stenosis, Systemic fluorouracil, Tear duct fibrosis
Abstract. Ocular side effects of systemic fluorouracil include excessive lacrimation, due to 
punctal and canalicular stenosis and fibrosis. Obstruction of the tear ducts after systemic 
therapy with fluorouracil is more frequent than is assumed. Five patients with breast cancer 
and punctal or canalicular stenosis are presented. Although complaints of epiphora usually 
resolve two weeks after cessation of systemic therapy, local antibiotics and steroids may be 
indicated. In patients with persisting complaints, and patients treated with fluorouracil for a 
prolonged period of time, prophylactic intubation of the tear ducts with silastic tubes has been 
advocated. (Conjunctivo)dacryocystorhinostomy may be unavoidable.
Introduction
Fluorouracil is a pyrimidine analogue inhibiting DNA synthesis and is com­
monly used in the treatment of carcinomas of the breast, and of the gastroin­
testinal and genitourinary tract. Systemic therapy with fluorouracil may lead 
to a variety of ocular complications. Ocular toxicity includes blurred vision, 
accommodation disorders, oculomotor disturbances, nystagmus, photopho­
bia, keratoconjunctivitis, optic neuropathy, ocular pain, periorbital edema, 
blepharitis, blepharospasm, ankyloblepharon, hyperemia and hyperpigmen­
tation of the eyelids, cicatricial ectropion, epiphora, chronic canaliculitis, and 
dacryofibrosis and stenosis [1-23].
In the literature, only seven cases of excessive lacrimation associated with 
systemic therapy with fluorouracil have been reported [4, 9, 17, 19]. We 
present five additional patients with complaints of epiphora after systemic
therapy with fluorouracil.
Patients
Case 1. In April 1990, a 61-year-old female patient was referred because 
of excessive lacrimation of both eyes. Complaints had started in may 1989,
2when systemic administration of fluorouracil and tamoxifen was commenced 
because of breast cancer. Examination disclosed complete occlusion of all 
lacrimal puncta. A membrane overlying the puncta was surgically removed 
and local treatment with antibiotics and steroids was administered for two 
weeks. However, complaints did not resolve. Conjunctivodacryocystorhinos- 
tomy was refused by the patient.
Case 2. A 62-year-old woman with breast cancer had been referred in Septem­
ber 1992 because of tearing eyes. Until January 1992 she had been treated 
with tamoxifen, which therapy was changed to a combination of cyclophos­
phamide, methotrexate and fluorouracil (CMF) because of bone métastasés. 
Complaints of epiphora started directly after first administration of systemic 
chemotherapy. On ocular examination, stenosis of all puncta was identified. 
Probing of the tear duct revealed partial stenosis of the lower canaliculi in 
both eyes. Irrigation of the lacrimal sac to the nasopharynx was positive. 
Local treatment with steroids was started. However, complete obstruction of 
the right lower canaliculus was found two weeks later. After gentle prob­
ing of the lacrimal duct irrigation was positive. Therapy with local steroids 
was continued. After repeated probing and completion of systemic therapy 
with CMF after 11 months, local steroids could be discontinued and ocular 
complaints resolved.
Case 3. A 49-year-old female patient had primary breast cancer for five 
months and was treated with fluorouracil and tamoxifen for two months when 
she was referred in January 1993 because of epiphora for four weeks. Exam­
ination revealed severe stenosis of all puncta. Local therapy with steroids 
was initiated and the complaints resolved three weeks after cessation of flu­
orouracil therapy in April 1993.
Case 4. In June 1993 a 70-year-old woman with breast cancer was referred 
because of ocular pain for two years, which complaint started four weeks after 
systemic treatment with fluorouracil and tamoxifen. On examination stenosis 
of all puncta was diagnosed. Probing the lower canaliculi of both eyes, a 
resistance was found. After piercing a membrane-like structure, irrigation of 
both lacrimal sacs to the nose was positive. Artificial tears were prescribed 
and complaints diminished.
Case 5. In September 1993 a 70-year-old female patient treated with flu­
orouracil and tamoxifen since January 1993 because of breast cancer had 
complaints of epiphora of both eyes for seven months. At examination severe 
stenosis of the lower punctum of the right eye was diagnosed with com-
3plete occlusion of the canaliculus. On the left complete stenosis of the lower 
punctum was found. Conjunctivodacryocystorhinostomy on the right was 
performed in January 1994 with favorable results.
Discussion
Chronic tearing eyes are tedious, the more so when excessive lacrimation is 
iatrogenic.
Fluorouracil inhibits DNA synthesis in rapidly proliferating tissues as the 
cornea epithelium, conjunctiva and tear duct, and may lead to inflammation. It 
has been proved that fluorouracil has severe toxic effects to the ocular surface 
epithelium [18]. This may give rise to increased reflex lacrimal secretion due 
to irritation to cornea and conjunctiva or reduced basal tear secretion [12]. 
Inflammation may lead to scarring and stenosis of the tear ducts resulting in 
obstruction of the lacrimal system and complaints of excessive lacrimation 
[4,5,9,10,17]. Cicatricial ectropion, due to skin changes in the eyelids, may 
also cause epiphora [19].
Christophidis et al. [5] measured the concentration of fluorouracil in both 
tears and plasma in eight patients with carcinoma of the colon treated with 
systemic fluorouracil. In three patients with complaints of excessive lacrima­
tion, fluorouracil could be detected both in tears and in plasma. However in 
five patients without ocular complaints, no fluorouracil was detectable in tear 
fluid. The concentration in plasma was comparable to the concentration in 
patients without complaints. Therefore, excessive lacrimation seemed to be 
related to penetration of fluorouracil in tear fluid. Loprinzi etal. [1.5] were able 
to detect fluorouracil in the tear fluid of 12 patients. Contrary to Christophidis 
et al. [5], they did not find a correlation of fluorouracil tear concentration with 
ocular complaints.
Fluorouracil has been used in patients with glaucoma to inhibit fibrosis and 
closure of the fistula following filtering procedures. However, in these cases, 
treatment with topical fluorouracil is limited to a short period of time and in 
case of local application the area treated is elaborately irrigated afterwards to 
avoid the toxic effects of fluorouracil to ocular surface epithelium. Further­
more, mitotic rate of conjunctival cells is decreased [6, 14, 18]. In patients 
with epiphora associated with systemic fluorouracil therapy for a prolonged 
period of time (months), chronic excretion of fluorouracil in tears may lead 
to inflammation, scarring and stenosis of the tear ducts and complaints of 
epiphora.
Epiphora has rarely been mentioned after systemic therapy with adri- 
amycin [3], doxorubicin [8] and methotrexate [7]. From tamoxifen, epiphora 
as an ocular complication has not been reported.
4Tearing eyes are described in one third of patients treated with CMF or 
with fluorouracil alone appearing gradually after starting fluorouracil therapy 
[5, 10,15]. In the literature only seven patients with stenosis of the tear duct 
associated with systemic fluorouracil therapy have been reported. Straus et aL 
[19] described a 61 -year-old male patient with presumed pancreatic carcinoma 
treated with systemic fluorouracil. Cicatricial ectropion was diagnosed and 
the lacrimal ducts were obstructed. Surgical correction of the ectropion did 
not affect the complaints of lacrimation. Haidak et al. [9] published the 
findings in a patient with obstructed canaliculi and scarring of the lacrimal 
sac. Biopsy revealed fibrosis of the punctum. Caravella et al. [4] described 
four patients with punctal and canalicular stenosis after systemic therapy 
with fluorouracil. In a 54-year-old female patient with carcinoma of the 
colon a mucosa-like membrane overlying the stenosed lacrimal puncta was 
detected. Slight stenosis of the lower canaliculus on the left was identified. 
Irrigation from the lacrimal sac to the nose was normal. A 5 8-year-old male 
patient with carcinoma of the colon presented with complete occlusion of the 
inferior punctum on the right, due to a mucosa-like membrane. Stenosis of 
the other three puncta and of the lower left canaliculus was found. Irrigation 
of the sac to the nasopharynx was normal. A 38-year-old female patient 
with adenocarcinoma of the small bowel presented with severe stenosis of 
all four puncta and canaliculi with normal irrigation of the lacrimal sac 
to the nose. She was treated with intubation of the tear ducts with silastic 
tubes with favorable results. A 43-year-old female patient treated with a
combination of fluorouracil and methotrexate because of breast cancer, was
0
seen because of complaints of epiphora due to stenosis of the lower lacrimal 
punctum on the right. Finally, Seiff et al. [17] described a 69-year-old female 
patient treated with fluorouracil because of pancreatic carcinoma, presenting 
with complete punctal and canalicular obstruction of both eyes. Bilateral 
conjunctivodacryocystorhinostomy was performed with favorable results.
In three of our patients, local therapy with antibiotics and/or steroids, 
whether or not with removal or piercing of a membrane overlying the punc­
tum or obstructing the canaliculi, resulted in resolution of the complaints 
of excessive lacrimation. Examination in two patients disclosed complete 
stenosis. In one patient complaints resolved after conjunctivodacryocystorhi- 
nostomy.
Complaints of epiphora usually resolve spontaneously one or two weeks 
after cessation of systemic fluorouracil therapy. Symptomatic relief of cro­
molyn and of placing ice packs on the eyes during fluorouracil injection has 
been reported. However, local therapy consisting of antibiotics and steroids 
may be indicated to prevent complete punctal or canalicular stenosis. In 
patients with persisting complaints of excessive lacrimation, prophylactic
5intubation of the tear ducts with silicon tubes is advocated. In some patients
surgical treatment as (conjunctivo)dacryocystorhinostomy may be necessary
[4,12, 15,17].
Stenosis and fibrosis of tear ducts are serious complications of systemic 
fhiorouracil and appear to be more common than is assumed. Fluorouracil 
treated patients should be monitored carefully for ophthalmic complications. 
Persisting tearing eyes need ophthalmic consultation.
References
1. Adams JW, Bofenkamp TM, Kobrin J, Wirtschafter JD, Zeese JA. Recurrent acute toxic 
optic neuropathy secondary to 5-FU. Cancer Treat Rep 1984; 68: 565-566.
2. Bixenman WW, Nicholls JW , Warwick OH. Oculomotor disturbances associated with 
5-fluorouracil chemotherapy. Am J Ophthalmol 1977; 83; 789-793.
3. Blum RH. An overview of studies with adriamycin (NSC-123127) in the United States. 
Cancer Chemother Rep 1975; 6:247-251.
4. Caravella LP Jr, Bums JA, Zangmeister M. Punctal-canalicular stenosis related to sys­
temic fluorouracil therapy. Arch Ophthalmol 1981; 99: 284-286.
5. Christophidis N, Lucas I, Vajda FJE, Louis WJ. Lacrimation and 5-fluorouracil. Ann 
Intern Med 1978; 89: 574.
6. The Fluorouracil Filtering Surgery Study Group. Fluorouracil filtering surgery study 
one-year follow-up. Am J Ophthalmol 1989; 108: 625-635.
7. Fraunfelder FT, Meyer SM. Ocular toxicity of antineoplastic agents. Ophthalmology 
1983; 90: 1-3.
8. Griffin JD, Gamick MB. Eye toxicity of cancer chemotherapy: a review of the literature.
Cancer 1981; 48: 1539-1549.
9. Haidak DJ, Hurwitz BS, Yeung KY. Tear-duct fibrosis (dacryostenosis) due to 5- 
fluorouracil. Ann Intern Med 1978; 88; 657.
10. Hamersley J, Luce JK, Horentz TR, Burkholder MM, Pepper JJ, Excessive lacrimation 
from flurouracil treatment. JAMA 1973; 225: 747-748.
11. Horio T, Murai T, Ikai K. Photosensitivity due to a fluorouracil derivate. Arch Dermatol 
1978; 114: 1498-1500.
12. Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer chemother­
apy, Surv Ophthalmol 1989; 34: 209-230.
13. Insler MS, Helm CJ. Ankyloblepharon associated with systemic 5-fluorouracil treatment. 
Ann Ophthalmol 1987; 19: 374-375.
14. Knapp A, Heuer DK, Stem GA, Driebe WT. Serious corneal complications of glaucoma 
filtering surgery with postoperative 5-fluorouracil. Am J Ophthalmol 1987; 103: 183- 
187.
15. Loprinzi CL, Love RR, Garrity JA, Ames MM. Cyclophosphamide, methotrexate, and 
5-fluorouracil (CMF)-induced ocular toxicity. Cancer Investigation 1990; 8: 459-465.
16. Salminen L, Jantti V, Bronross M. Blepharospasm associated with tegafur combination 
chemotherapy. Am J Ophthalmol 1984; 97: 649-650.
17. Seiff SR, Shorr N, Adams T. Surgical treatment of punctal-canalicular fibrosis from 
5-fluorouracil therapy. Cancer 1985; 56: 2148-2149.
18. Shapiro MS, Thoft RA, Friend J, Parrish RK, Gressel MG. 5-Fluorouracil toxicity to the 
ocular surface epithelium. Invest Ophthalmol Vis Sei 1985; 26: 580-583.
19. Straus DJ, Mausolf FA, Ellerby RA, McCracken JD. Cicatricial ectropion secondary to 
5-fluorouracil therapy. Med Pediatr Oncol 1977; 3: 15-19.
620. Vizel M, Oster MW. Ocular side effects of cancer chemotherapy. Cancer 1982; 49: 
1999-2002.
21. Weiss AJ, Jackson LG, Carabisi R. An evaluation of 5-fluorouracil in malignant disease. 
Ann Intern Med 1961; 55:7734-7741.
22. Weiss HD, Walker MD, Wiemi PH. Neurotoxicity of commonly used antineoplastic 
agents. N Eng J Med 1974; 291: 75-81.
23. Zaal MJW, Polak BCP. Oogheelkundige bijwerkingen van het gebruik van cytostatica. 
Ned Tljdschr Geneeskd 1985; 129:1919-1921.
Address for correspondence: H.M. A. Brink, Institute of Ophthalmology, Nijmegen University 
Hospital, P. O. Box 9101,6500 HB Nijmegen, The Netherlands 
Phone: 080-615104; Fax: 080-540522
